神经活性类固醇
化学
γ-氨基丁酸受体
药理学
变构调节
受体
变构调节剂
别孕甾酮
神经科学
内科学
生物化学
心理学
医学
作者
Gabriel Martinez Botella,Francesco G. Salituro,Boyd L. Harrison,Richard T. Beresis,Zhu Bai,María‐Jesús Blanco,Gabriel M. Belfort,Jing Dai,Carlos M. Loya,Michael A. Ackley,Alison L. Althaus,Scott Grossman,Ethan Hoffmann,James Doherty,Albert J. Robichaud
标识
DOI:10.1021/acs.jmedchem.7b00846
摘要
Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors. Herein, we report new SAR insights in a series of 5β-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties. Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).
科研通智能强力驱动
Strongly Powered by AbleSci AI